AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00483080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W or q1W NGR-hTNF 0.8 μg/m²
Study NCT01398644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phlebotomy and erythrocytapheresis
Description: Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
Study NCT01398644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy and erythrocytapheresis
Description: Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
Study NCT01612767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRO-Kinetic Energy Stent
Description: Coronary artery stent implant
Study NCT04319614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Product
Description: A single dose of tranexamic acid, corresponding to 20 mg/kg in 100 ml saline, will be administered in the beginning of procedure.
Study NCT04319614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 100 ml of saline will be administered in the beginning of the procedure.
Study NCT01891890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Description: Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
Study NCT01891890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
Study NCT01891890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
Study NCT03436550 — intervention group
Intervention type: PROCEDURE
Intervention: mpMRI
Description: Multiparametric MRI
Study NCT03436550 — intervention group
Intervention type: PROCEDURE
Intervention: ARFI US
Description: Acoustic radiation force impulse is a type of ultrasound elastography
Study NCT01589549 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stromal cell therapy
Description: One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
Study NCT01589549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell therapy
Description: One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
Study NCT03772600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Use of Dexcom G6
Study NCT02996318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel coated balloon (SeQuent Please)
Description: Paclitaxel coated balloon (SeQuent Please)
Study NCT02996318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus coated balloon
Description: Sirolimus coated balloon
Study NCT03515200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Capsule
Description: Given orally or nasogastrically (NG).
Study NCT03515200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy
Description: Given intrathecally (IT).
Study NCT03515200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally, nasogastrically (NG) or intravenously (IV).
Study NCT03515200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given intravenously (IV) or subcutaneously (SC).
Study NCT03515200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given orally or nasogastrically (NG).
Study NCT03515200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given intravenously (IV).
Study NCT03515200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given orally or nasogastrically (NG).
Study NCT01143883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silverlon
Description: Silverlon dressings are gauze impregnated with silver ions
Study NCT01143883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dressing
Description: Standard dry gauze dressing
Study NCT00741468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: 2, 25 mg Proellex capsules administered daily
Study NCT00741468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP1A2 probe
Description: Caffeine (200 mg)
Study NCT00741468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2C9 probe
Description: Tolbutamide (250 mg)
Study NCT00741468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2C19 probe
Description: Omeprazole (20 mg)
Study NCT00741468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2D6 probe
Description: Dextromethorphan (30 mg)
Study NCT00741468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP3A4 probe
Description: Midazolam (2mg)
Study NCT01044836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD203
Description: Injectable form
Study NCT00865137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus, modified release
Description: Oral
Study NCT03906604 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Carpal Tunnel Procedure (open)
Description: Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.
Study NCT03017521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-117
Description: TAS-117 16mg, daily
Study NCT01846468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: 1 mg, 12.5 mg, 100 mg capsules
Study NCT01846468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules
Study NCT00428922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
Study NCT00428922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
Study NCT00428922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
Study NCT02696928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemeter-Lumefantrine and MB (combination therapy)
Description: AL first 3 days MB next 14 days
Study NCT02696928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artemeter-Lumefantrine (combination therapy)
Description: AL first 3 days
Study NCT02696928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemeter-Lumefantrine and Primaquine (combination therapy)
Description: AL first 3 days PQ next 14 days
Study NCT03938688 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesh placement with Transfascial Sutures
Description: Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
Study NCT02911259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction is set to -2 cmH2O
Description: Post-operative suction is set to -2 cmH2O (intervention).
Study NCT02911259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction is set to -10 cmH2O
Description: Post-operative suction is set to -10 cmH2O (standard treatment).
Study NCT00465543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mint tea high in rosmarinic acid
Description: Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
Study NCT00465543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mint tea low in rosmarinic acid
Description: Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
Study NCT03865394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Application of allogeneic ADSC stem cells in fibrin gel
Description: Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.
Study NCT03865394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care in diabetic foot ulcer
Description: Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.
Study NCT03124355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo sugar pill
Description: placebo single oral dose
Study NCT03124355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Pill
Description: pyridostigmine bromide 30 mg single oral dose
Study NCT03124355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine Pill
Description: Galantamine hydrobromide 8mg single oral dose
Study NCT03124355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal stimulation
Description: Vagal stimulation will be given at 50 Hz during the tilt table tests
Study NCT03124355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham vagal stimulation
Description: Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
Study NCT00681265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycerin
Description: Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
Study NCT00681265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 400/propylene glycol
Description: Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
Study NCT03704012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol of massage therapy and kinesiotherapy
Description: Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
Study NCT01449747 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin (100mg, per oral) once a day.
Study NCT01449747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin (100mg, per oral) once a day.
Study NCT02998619 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
Study NCT03917537 — intervention group
Intervention type: GENETIC
Intervention: HNSCC patients have used Nivolumab
Description: Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
Study NCT01125566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
Study NCT02649426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Paradise® Renal Denervation Ultrasound System
Description: Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
Study NCT02649426 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
Study NCT01840137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Strength Test
Description: A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
Study NCT01840137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Treadmill and muscle exercises.
Study NCT02644330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transthoracic device closure
Description: minimally invasive transthoracic device closure
Study NCT02644330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical repair
Description: surgical repair with cardiopulmonary bypass
Study NCT02013102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine Injection
Description: Decitabine Injection 20mg/m2/d\*5d, IV> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d\*8d, IV> 1h, one cycles per 4 weeks.
Study NCT02398513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib 160 mg per oral
Study NCT00006220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study NCT01125566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: patients receive trastuzumab 2mg/kg intravenously every week
Study NCT01125566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Description: patients receive vinorelbine 25mg/m² intravenously every week
Study NCT01125566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: patients receive vinorelbine 25mg/m² intravenously every week
Study NCT03796598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbial transplant Capsules
Description: Oral capsules of FMT
Study NCT03796598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbial transplant Capsules
Description: Oral capsules of FMT
Study NCT03796598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant Enema
Description: FMT enema
Study NCT03796598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbial Transplant Enema
Description: FMT enema
Study NCT03796598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03796598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04192539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
Study NCT00876499 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
Study NCT01149876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nu Skin Product
Description: Thin layer of Nu Skin product applied to face.
Study NCT01149876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic instrument
Description: Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
Study NCT01149876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin cream 0.05
Description: Thin layer of tretinoin applied to face.
Study NCT01149876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CeraVe moisturizer
Description: Thin layer of CeraVe applied to face.
Study NCT02675218 — intervention group
Intervention type: OTHER
Intervention: Patients with rheumatoid arthritis
Description: Doppler effect at 3 months after Abatacept treatment initiation.
Study NCT04400799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml
Description: daily incetion s.c. for 14 days
Study NCT01510132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/timolol fixed combination (Travacom)
Description: Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
Study NCT04303546 — intervention group
Intervention type: DEVICE
Intervention: arterial stiffness measurements
Description: We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
Study NCT03895697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon analogue
Study NCT03745586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals
Study NCT03745586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Day0-day2: methylprednisolone 500mg i.v.
Study NCT04137861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bioceramics
Description: root repair material
Study NCT04137861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioceramics
Description: root repair material
Study NCT00269841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
Study NCT00269841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
Study NCT00269841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be adminstered at Week 0, 2 and 6.
Study NCT00988117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Patch 9.5 cm2
Description: Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
Study NCT02854397 — intervention group
Intervention type: OTHER
Intervention: blood sample
Study NCT01684111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 2 x 150 mg capsules, oral, daily (Start dose)
Study NCT01684111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
Study NCT01993628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rey figure test
Study NCT01993628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02180347 — intervention group
Intervention type: DEVICE
Intervention: Contact lenses
Study NCT03557242 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement
Study NCT03557242 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Warfarin plus Aspirin
Description: Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR
Study NCT03557242 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aspirin Only
Description: Subjects randomized to this arm will receive aspirin only post TAVR
Study NCT03115671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vayarin
Description: Vayarin capsule
Study NCT03769077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
Study NCT01044901 — intervention group
Intervention type: PROCEDURE
Intervention: MRI, Transthoracic Echocardiography, tonometry, EKG
Description: Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
Study NCT00185796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Description: TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1